Gliclazide Immediate-Release Dosing Regimen
For immediate-release (non-modified release) gliclazide, doses up to 80 mg should be given once daily at breakfast, while doses exceeding 80 mg should be divided into twice-daily administration (BD), with a maximum total daily dose of 320 mg. 1
Dosing Algorithm
Initial Dosing
- Start with 40-80 mg once daily at breakfast for most patients 1
- For patients with renal impairment (eGFR 30-50 mL/min/1.73 m²), initiate conservatively at lower end of range due to hypoglycemia risk 2
Dose Escalation Strategy
- If total daily dose ≤80 mg: Administer as single morning dose (OD) 1
- If total daily dose >80 mg: Split into twice-daily dosing (BD) - typically before breakfast and dinner 1
- Maximum dose: 320 mg daily (divided doses if >80 mg) 1
Titration Timeline
Based on real-world evidence, progressive uptitration shows:
- 15% reach optimal dose by month 1
- 39% by month 2
- 59% by month 3
- 92% by month 6 3
Key Clinical Considerations
Why the 80 mg Threshold Matters
The immediate-release formulation lacks the hydrophilic matrix technology of modified-release gliclazide, resulting in less consistent 24-hour coverage 4. Dividing doses >80 mg provides better glycemic control throughout the day and reduces hypoglycemia risk by avoiding excessive peak concentrations 5.
Common Pitfall to Avoid
Do not continue escalating gliclazide beyond 15-20 mg daily if glycemic targets are not met - further dose increases rarely provide meaningful benefit and increase hypoglycemia risk. Instead, consider switching to insulin or adding agents with cardiovascular/renal benefits (SGLT2 inhibitors or GLP-1 receptor agonists) 2.
Renal Function Assessment
- eGFR >50 mL/min/1.73 m²: No dose adjustment needed 2
- eGFR 30-50 mL/min/1.73 m²: Use conservative dosing, titrate slowly 2
- eGFR <30 mL/min/1.73 m²: Consider alternative agents 2
Special Population: Ramadan Fasting
For Muslim patients observing Ramadan with twice-daily dosing, take half the usual morning dose at predawn meal and full dose at sunset meal 6, 1